Preclinical data are supportive but do not change the risk/reward calculus for a clinical-stage biotech. Watch for enrollment updates from the Phase 2 trial (NCT07550088) and any future clinical readouts for agenT-797 in solid tumors or GVHD.
Price Chart
Executive Summary
MiNK Therapeutics presented preclinical data at SITC 2026 showing agenT-797 enables tumor-cell killing in a checkpoint inhibitor-resistant colorectal cancer liver metastases model and that native/engineered iNKT cells eliminate senescent tumor cells and fibroblasts. The data support the ongoing Phase 2 trial of agenT-797 + botensilimab/balstilimab in MSS metastatic colorectal cancer and highlight platform versatility, but remain preclinical with no new clinical results or financial disclosures.
Key Facts
- Two poster presentations at SITC 41st Annual Meeting (Nov 6-7, 2026).
- agenT-797 alone and with BOT+BAL showed tumor-cell killing in a human organoid model of checkpoint inhibitor-refractory colorectal cancer liver metastases.
- Preclinical data support ongoing Phase 2 trial (NCT07550088) at Scripps in MSS metastatic colorectal cancer with liver metastases.
- Native agenT-797 and engineered MiNK-215 (FAP-targeting CAR-iNKT with IL-15) eliminated senescent tumor cells and fibroblasts in vitro.
- No new clinical efficacy, safety, or financial data disclosed.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to clinical efficacy.
- No new clinical data or financial runway disclosed.
- Competition from other cell therapy platforms in solid tumors.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373825 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 144 | $10.23 | awaiting T+20 | — | $10.80 (+5.57%) |
Oct 2, 2026 25d ago | Press Release | $12.44 | awaiting T+20 | — | $10.80 (−13.18%) |
Aug 13, 2026 10w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $10.80 (−1.82%) |
Aug 13, 2026 10w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $10.80 (−1.82%) |
Aug 6, 2026 11w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $10.80 (−1.82%) |
May 28, 2026 21w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $10.80 (−11.48%) |
May 20, 2026 22w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $10.80 (+0.75%) |
May 15, 2026 23w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $10.80 (+0.75%) |
May 15, 2026 23w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $10.80 (+0.75%) |
May 14, 2026 23w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $10.80 (+2.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers